Zytiga (abiraterone), approved since 2011 for use in prostate cancer, is its biggest selling cancer drug, and saw sales jump 45.5% compared with last year’s Q4 to $755 million. Full-year sales ...

The UK's cost-effectiveness watchdog has previously backed the use of Zytiga (abiraterone) for treating advanced prostate cancer after docetaxel-containing chemotherapy, but stopped short of ...

Capivasertib combination shows promise in mHSPC vs the placebo combination, LBS-007 received fast track designation, and RP1 plus nivolumab submitted a BLA application. We also cover a retrospective ...

Abiraterone (Zytiga) is an oral, selective and potent irreversible inhibitor of CYP17A, which is an enzyme that catalyzes both 17 alpha-hydroxylase and 17, 20-lyase reactions. It blocks androgen ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adding capivasertib (Truqap) to abiraterone (Zytiga) and androgen deprivation therapy improved radiographic progression ...

Among patients with PTEN-deficient metastatic hormone-sensitive prostate cancer, Truqap (capivasertib) combined with Zytiga (abiraterone acetate) and androgen deprivation therapy (ADT) demonstrated a ...

Abiraterone, also known as Zytiga, is a hormone therapy. Unlike chemotherapy which kills the cancerous cells, it stops more testosterone from reaching the prostate gland to stifle the tumour's growth.

We discovered the drug abiraterone (Zytiga) – now a mainstay of treatment for advanced prostate cancer across the world. Along with our partner hospital The Royal Marsden, we ran clinical trials to ...